Agenda

An overview of opportunities associated with early biomarker investment for enhancing the demonstration of drug efficacies in target populations

• An overview of opportunities associated with early biomarker investment for enhancing the demonstration of drug efficacies in target populations
• How to effectively deploy a drug-Dx co-development strategy as part of your next therapeutic program
• Establishing successful prelaunch partnerships to ensure candidates are commercially ready and patient access is maximized
• Actionable insights into leveraging the existing disease landscape to ensure suitable reimbursement is in place for launch
• Insight on which in-market activities can facilitate the maximum uptake of your co-developed drug and Dx

During this session, experts in precision diagnostics, targeted therapy and healthcare delivery will discuss a first-of-its-kind landscape analysis applying a quantitative multi-factorial framework to assess the clinical adoption of personalized medicine in health care throughout the United States. Based on a survey of a representative sample of 153 health care providers, the analysis , which was commissioned by the Personalized Medicine Coalition, shows that 83 percent of the institutions studied scored a two or higher on the five-point scale used to examine their integration efforts. The study also showed that only 22 percent of the institutions studied scored a four or a five on the personalized medicine integration scale. Panelists will discuss this system-wide but incomplete push to implement personalized medicine in clinical settings, highlighting both the momentum that the field has as well as the limitations associated with the utilization of new precision medicine technologies and practices with extraordinary but understudied potential benefits.